Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Crohn's disease(CD),a type of inflammatory bowel disease(IBD), is a chronic intestinal recurrent inflammatory disease involving the entire digestive tract. And Ustekinumab, a monoclonal antibody against the p40 subunit of interleukin-12 and interleukin-23, is a newly targeted drug approved for the treatment of Crohn's disease in recent years.Based on the high-throughput imaging characteristic analysis technique, this study quantitatively analyzed the transmural inflammation of Crohn's disease, and discussed its prognostic value in the treatment of Ustekinumab, and further analyzed the increment of its relative clinical index.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| CD patients who received Ustekinumab treatment | 1. Inpatients with Crohn's disease diagnosed in the Sixth Affiliated Hospital of Sun Yat-Sen University from January 2020 to June 2022. 2.The patients were treated with Ustekinumab and followed up regularly for 20 weeks. 3. Complete pre-treatment cross-sectional imaging data (CTE/MRE and US) |
Not provided
| Measure | Description | Time Frame |
|---|---|---|
| endoscopic remission rate at 12 months | endoscopic remission rate at 12 months | 12 months after first intervention administration |
| normalization rate of serum biomarker at 12 months | normalization rate of serum biomarker at 12 months | 12 months after first intervention administration |
| clinical remission rate at 12 months | clinical remission rate at 12 months | 12 months after first intervention administration |
| clinical response rate at 12 months | clinical response rate at 12 months | 12 months after first intervention administration |
| endoscopic response rate at 12 months | endoscopic response rate at 12 months | 12 months after first intervention administration |
| life quality changes at 12 months | life quality evaluated by CDAI (Crohn's Disease Activity Index) at 12 months | 12 months after first intervention administration |
| endoscopic remission rate after induction therapy | endoscopic remission rate after induction therapy | 16 or 20 weeks after first intervention administration |
| normalization rate of serum biomarker after induction therapy |
Not provided
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
January 2020 to June 2022 CD patients in the IBD center of Sixth Affiliated Hospital of Sun Yat-Sen University, who were treated with Ustekinumab.
Not provided
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| the Sixth Affiliated Hospital of Sun Yat-Sen University | Guangzhou | Guangdong | 501655 | China |
Not provided
Not provided
Not provided
Not provided
normalization rate of serum biomarker after induction therapy |
| 16 or 20 weeks after first intervention administration |
| clinical remission rate after induction therapy | clinical remission rate after induction therapy | 16 or 20 weeks after first intervention administration |
| clinical response rate after induction therapy | clinical response rate after induction therapy | 16 or 20 weeks after first intervention administration |
| endoscopic response rate after induction therapy | endoscopic response rate after induction therapy | 16 or 20 weeks after first intervention administration |
| life quality changes after induction therapy | life quality evaluated by CDAI (Crohn's Disease Activity Index) after induction therapy | 16 or 20 weeks after first intervention administration |
| ID | Term |
|---|---|
| D015212 | Inflammatory Bowel Diseases |
| D003424 | Crohn Disease |
| ID | Term |
|---|---|
| D005759 | Gastroenteritis |
| D005767 | Gastrointestinal Diseases |
| D004066 | Digestive System Diseases |
| D007410 | Intestinal Diseases |
Not provided
Not provided